The pelvic reconstruction market is anticipated to flourish at an average CAGR of 2.8% between 2023 and 2033. The market is expected to hold a market share of US$ 376.2 million by 2033, while the market is likely to reach a value of US$ 285.6 million in 2023.
Vaginal sling systems are among the most widely manufactured pelvic reconstruction products worldwide. Vaginal slings use minimally invasive procedures that are less time-consuming and aid in treating conditions such as urinary incontinence. These slings are placed in the urethra to keep the urethra in the correct position. As per the study, vaginal mesh and vaginal sling systems may continue to grow in the forecast period (2023 to 2033).
As per the National Center for Biotechnology Information, around 40% of women across the globe are affected with urinary incontinence. It is one of the key causes resulting in the need for pelvic repair due to abnormalities caused by these diseases. To limit the condition, urethral sling procedures, also known as pubovaginal slings, are the most preferred among healthcare professionals. This is expected to aid the growth of the market.
| Attributes | Details |
|---|---|
| Pelvic Reconstruction Market CAGR (2023 to 2033) | 2.8% |
| Pelvic Reconstruction Market Size (2023) | US$ 285.6 million |
| Pelvic Reconstruction Market Size (2033) | US$ 376.2 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), pelvic reconstruction was nearly 1.1% of the US$ 25.0 million global women's health devices market in 2022. The sales of pelvic reconstruction expanded at a CAGR of 2.3% from 2018 to 2022 due to the increasing prevalence of pelvic organ prolapse.
The demand for pelvic reconstruction procedures is expected to significantly increase due to growing pelvic floor problems such as vaginal prolapse, urinary incontinence, interstitial cystitis, and fistulae. Due to this, the demand for both surgical and non-surgical procedures is predicted to surge rapidly, fuelling the growth.
As per the study, the recurrence rate among patients is also high for pelvic organ prolapse. It is a highly common case in women; per the United States Department of Health and Human Services, pelvic floor disorders, including urinary incontinence and pelvic organ prolapse, affect one in five women.
The traditional treatment methods are replaced by robotic surgeries that are minimally invasive and lead to faster recovery. Also, with the complications associated with the use of synthetic mesh in pelvic floor repair, healthcare professionals are actively researching the use of biomaterials and cell-based therapies.
Further, tissue engineering using several different cell lines, including fibroblasts and adult stem cells, has been proposed to be used within the pelvic floor. Consequently, companies are investing extensively in research and technology to improve the treatment pattern and reduce the current treatment's risks and side effects.
Considering women's health and access to safe and effective medical devices, the United States Food and Drug Administration (FDA) are analyzing the benefit and risks of surgical mesh. In 2019, the FDA issued warnings about the risks associated with using transvaginal mesh used for pelvic organ prolapse (POP) repair with the use of certain devices.
Vaginal mesh, vaginal sling systems, and vaginal pessaries are projected to be in high demand in the forecast period as the prevalence of pelvic floor disorder rises. Vaginal sling systems are widely used owing to the minimally invasive procedure and increased cases of pelvic floor disorders, especially among the female population.
Owing to the aforementioned factors, the global pelvic reconstruction market is expected to record a CAGR rate of 2.8% during the forecast period.
Need for Alternative Procedure Due to Complexities in Current to Create Conducive Environment
Development and surveillance of novel tissue engineering procedures, such as cell-based therapies for pelvic floor reconstruction, are key factors creating lucrative growth prospects for the market.
As there are numerous complexities associated with the current procedures and with the prohibitions by the FDA for certain transvaginal mesh products, the demand for alternatives, such as tissue engineering procedures, may surge.
It is an innovative approach that could be worked upon immensely by the manufacturers for the increased growth in the market of pelvic reconstruction. This is expected to provide lucrative opportunities for growth in the overall pelvic reconstruction market.
Principal Consultant
Side-effects by Use of Surgical Mesh Might Impede the Growth
There is a decrease in products concerning pelvic reconstruction owing to the disapproval and ban of certain products by regulatory authorities such as the FDA. Some common complications reported include mesh erosion, infections, vaginal scarring, and a recurrence of urinary incontinence.
Several adverse events were reported with surgical mesh, a key restrain in the market growth. For instance, the POP Mesh Adverse Event Reports to the FDA, through January 31, 2019, were 139,000 for mesh products, over 132,280 of these were injuries and 1,107 patients died. These factors are likely to affect the pelvic reconstruction market negatively.
| Country | Revenue Share % (2022) |
|---|---|
| United States | 29.7% |
| Germany | 5.1% |
| Japan | 3.2% |
| North America | 33.9% |
| Europe | 26.5% |
| Country | CAGR % (2023 to 2033) |
|---|---|
| China | 3.5% |
| India | 3.7% |
| United Kingdom | 2.3% |
| Australia | 3.0% |
Ongoing Product Development and Research Activities by Leading Companies to Augment Growth
The United States held around 29.7% of the global pelvic reconstruction market in 2022. The North American region held a market share of 33.9% in 2022. As per the study, many women in the United States face the complexities of pelvic organ prolapse (POP). This is resulting in high demand for pelvic reconstruction procedures.
To capitalize on this growing demand, leading players such as Johnson & Johnson and Boston Scientific are investing in research and development to develop efficient procedures. For instance, in July 2022, a leading player in the United States, Onkos Surgical, announced the approval of its My3D Personalized Pelvic Reconstruction System.
It is a first-of-a-kind solution that provides 3D-printed implants, models, and instruments and an advanced planning service to treat deformities, revisions, and diseases efficiently. The implants are designed and manufactured with unique features that provide an accurate way for anatomic restoration. Hence, a slew of such developments in the United States may boost the market.
Rising Incidence of Pelvic Disorders in the United Kingdom to Propel Demand
The United Kingdom dominated the Europe pelvic reconstruction market with a total market share of about 24.1% in 2022 and is expected to witness an average CAGR of 2.3% between 2023 and 2033. Rising cases of pelvic floor disorders in the country underpin growth in the market. As per the BMJ, in 2022, around 5 million women in the United Kingdom experience pelvic floor dysfunction.
With burgeoning cases of pelvic disorders, the need for non-invasive pelvic reconstruction procedures is expected to surge. Hence, numerous key players are eyeing the United Kingdom market to capitalize on this trend and gain revenue. Besides this, the availability of favorable reimbursement policies in the United Kingdom's healthcare infrastructure is aiding the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | By Product Type |
|---|---|
| Leading Segmente | Vaginal Sling Unit |
| Market Share (2022) | 54.20% |
| Category | By Procedure Type |
|---|---|
| Leading Segmente | Surgical |
| Market Share (2022) | 78.9% |
Vaginal Sling Systems to Remain the Most Preferred Procedure for Pelvic Reconstruction
Based on product type, the vaginal sling systems segment held a market share of 54.20% in 2022. The segment contributed revenue of around 54.2% of the demand share in 2021. Vaginal sling systems are preferred as it is considered the best option for the minimally invasive procedure and has a short patient recovery time.
Increasing POP Cases to Propel the Need for Surgical Procedures
Surgical procedures held a revenue share of 78.9% in 2022, and the segment is predicted to expand positively due to the success rates for reconstructive surgeries. With rising cases of pelvic floor disorders, the need for surgical procedures is growing as it is proven to be the most successful and preferable way to treat the disorder.
In terms of indication, pelvic organ prolapse is the most common indication globally. The segment held a market share of about 53.7% in 2021. An increase in pelvic organ prolapses due to aging and trauma during childbirth, such as difficult labor, obesity, chronic cough, or chronic constipation, may aid the demand for pelvic reconstructive surgeries.
Hospitals held a huge market share of 48.9% in 2022, per Future Market Insights (FMI). The growing prevalence of pelvic floor disorders and the increase in surgical and non-surgical procedures are driving the growth in the segment. Due to the easy availability of all advanced products and healthcare equipment, the adoption of pelvic reconstructive products has surged in hospitals worldwide.
Further, skilled professionals and on-call surgeons are available in hospitals, especially in developed countries such as the United States and the United Kingdom. Additionally, in emerging economies such as India and China, patients can avail of reimbursement policies, which makes the surgical procedure in hospitals cost-effective. This may boost the growth in the segment.
The pelvic reconstruction production industry is highly fragmented, with numerous competitors. Leading manufacturers are adopting strategies like enhanced research and development and expansion to meet consumer demand and grow their customer base.
For instance:
Key Players
The market held a value of US$ 277.8 million in 2022.
The market holds a value of US$ 285.6 million in 2023.
The market is anticipated to hold a share of US$ 376.2 million by 2033.
The market is expected to have a CAGR of 2.8% by 2033.
The vaginal sling system segment leads the market as it held a market share of 54.20% in 2022.
The surgical segment leads the market as it held a market share of 78.9% in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Vaginal Mesh
5.3.1.1. Biological Mesh
5.3.1.2. Synthetic Mesh
5.3.2. Vaginal Sling Systems
5.3.3. Vaginal Pessary
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Procedure
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Procedure, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Procedure, 2023 to 2033
6.3.1. Non-Surgical
6.3.2. Surgical
6.3.2.1. Obliterative surgery
6.3.2.2. Reconstructive surgery
6.3.3. Native Tissue Repair
6.3.4. Colporrhalphy
6.3.5. Sacrocolpopexy
6.3.6. Sacrohysteropexy
6.3.7. Transvaginal graft
6.3.8. Sling Surgery
6.4. Y-o-Y Growth Trend Analysis By Procedure, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Procedure, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033
7.3.1. Pelvic Organ Prolapse
7.3.2. Vaginal Prolapse
7.3.3. Rectal Prolapse
7.3.4. Urinary Incontinence
7.3.5. Interstitial Cystitis
7.3.6. Fistulae
7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Pelvic Organs
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Pelvic Organs, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pelvic Organs, 2023 to 2033
8.3.1. Uterus
8.3.2. Ovaries
8.3.3. Vagina
8.3.4. Fallopian Tubes
8.4. Y-o-Y Growth Trend Analysis By Pelvic Organs, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Pelvic Organs, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Specialty Clinics
9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. South Asia and Pacific
10.3.6. East Asia
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. USA
11.2.1.2. Canada
11.2.2. By Product
11.2.3. By Procedure
11.2.4. By Indication
11.2.5. By Pelvic Organs
11.2.6. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Procedure
11.3.4. By Indication
11.3.5. By Pelvic Organs
11.3.6. By End User
11.4. Key Takeaways
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Product
12.2.3. By Procedure
12.2.4. By Indication
12.2.5. By Pelvic Organs
12.2.6. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Procedure
12.3.4. By Indication
12.3.5. By Pelvic Organs
12.3.6. By End User
12.4. Key Takeaways
13. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. UK
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Western Europe
13.2.2. By Product
13.2.3. By Procedure
13.2.4. By Indication
13.2.5. By Pelvic Organs
13.2.6. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Procedure
13.3.4. By Indication
13.3.5. By Pelvic Organs
13.3.6. By End User
13.4. Key Takeaways
14. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Poland
14.2.1.2. Russia
14.2.1.3. Czech Republic
14.2.1.4. Romania
14.2.1.5. Rest of Eastern Europe
14.2.2. By Product
14.2.3. By Procedure
14.2.4. By Indication
14.2.5. By Pelvic Organs
14.2.6. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Procedure
14.3.4. By Indication
14.3.5. By Pelvic Organs
14.3.6. By End User
14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. India
15.2.1.2. Bangladesh
15.2.1.3. Australia
15.2.1.4. New Zealand
15.2.1.5. Rest of South Asia and Pacific
15.2.2. By Product
15.2.3. By Procedure
15.2.4. By Indication
15.2.5. By Pelvic Organs
15.2.6. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Procedure
15.3.4. By Indication
15.3.5. By Pelvic Organs
15.3.6. By End User
15.4. Key Takeaways
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. China
16.2.1.2. Japan
16.2.1.3. South Korea
16.2.2. By Product
16.2.3. By Procedure
16.2.4. By Indication
16.2.5. By Pelvic Organs
16.2.6. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product
16.3.3. By Procedure
16.3.4. By Indication
16.3.5. By Pelvic Organs
16.3.6. By End User
16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Product
17.2.3. By Procedure
17.2.4. By Indication
17.2.5. By Pelvic Organs
17.2.6. By End User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Product
17.3.3. By Procedure
17.3.4. By Indication
17.3.5. By Pelvic Organs
17.3.6. By End User
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2022
18.1.2.1. By Product
18.1.2.2. By Procedure
18.1.2.3. By Indication
18.1.2.4. By Pelvic Organs
18.1.2.5. By End User
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2022
18.2.2.1. By Product
18.2.2.2. By Procedure
18.2.2.3. By Indication
18.2.2.4. By Pelvic Organs
18.2.2.5. By End User
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2022
18.3.2.1. By Product
18.3.2.2. By Procedure
18.3.2.3. By Indication
18.3.2.4. By Pelvic Organs
18.3.2.5. By End User
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2022
18.4.2.1. By Product
18.4.2.2. By Procedure
18.4.2.3. By Indication
18.4.2.4. By Pelvic Organs
18.4.2.5. By End User
18.5. Germany
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2022
18.5.2.1. By Product
18.5.2.2. By Procedure
18.5.2.3. By Indication
18.5.2.4. By Pelvic Organs
18.5.2.5. By End User
18.6. UK
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2022
18.6.2.1. By Product
18.6.2.2. By Procedure
18.6.2.3. By Indication
18.6.2.4. By Pelvic Organs
18.6.2.5. By End User
18.7. France
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2022
18.7.2.1. By Product
18.7.2.2. By Procedure
18.7.2.3. By Indication
18.7.2.4. By Pelvic Organs
18.7.2.5. By End User
18.8. Spain
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2022
18.8.2.1. By Product
18.8.2.2. By Procedure
18.8.2.3. By Indication
18.8.2.4. By Pelvic Organs
18.8.2.5. By End User
18.9. Italy
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2022
18.9.2.1. By Product
18.9.2.2. By Procedure
18.9.2.3. By Indication
18.9.2.4. By Pelvic Organs
18.9.2.5. By End User
18.10. Poland
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2022
18.10.2.1. By Product
18.10.2.2. By Procedure
18.10.2.3. By Indication
18.10.2.4. By Pelvic Organs
18.10.2.5. By End User
18.11. Russia
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2022
18.11.2.1. By Product
18.11.2.2. By Procedure
18.11.2.3. By Indication
18.11.2.4. By Pelvic Organs
18.11.2.5. By End User
18.12. Czech Republic
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2022
18.12.2.1. By Product
18.12.2.2. By Procedure
18.12.2.3. By Indication
18.12.2.4. By Pelvic Organs
18.12.2.5. By End User
18.13. Romania
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2022
18.13.2.1. By Product
18.13.2.2. By Procedure
18.13.2.3. By Indication
18.13.2.4. By Pelvic Organs
18.13.2.5. By End User
18.14. India
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2022
18.14.2.1. By Product
18.14.2.2. By Procedure
18.14.2.3. By Indication
18.14.2.4. By Pelvic Organs
18.14.2.5. By End User
18.15. Bangladesh
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2022
18.15.2.1. By Product
18.15.2.2. By Procedure
18.15.2.3. By Indication
18.15.2.4. By Pelvic Organs
18.15.2.5. By End User
18.16. Australia
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2022
18.16.2.1. By Product
18.16.2.2. By Procedure
18.16.2.3. By Indication
18.16.2.4. By Pelvic Organs
18.16.2.5. By End User
18.17. New Zealand
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2022
18.17.2.1. By Product
18.17.2.2. By Procedure
18.17.2.3. By Indication
18.17.2.4. By Pelvic Organs
18.17.2.5. By End User
18.18. China
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2022
18.18.2.1. By Product
18.18.2.2. By Procedure
18.18.2.3. By Indication
18.18.2.4. By Pelvic Organs
18.18.2.5. By End User
18.19. Japan
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2022
18.19.2.1. By Product
18.19.2.2. By Procedure
18.19.2.3. By Indication
18.19.2.4. By Pelvic Organs
18.19.2.5. By End User
18.20. South Korea
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2022
18.20.2.1. By Product
18.20.2.2. By Procedure
18.20.2.3. By Indication
18.20.2.4. By Pelvic Organs
18.20.2.5. By End User
18.21. GCC Countries
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2022
18.21.2.1. By Product
18.21.2.2. By Procedure
18.21.2.3. By Indication
18.21.2.4. By Pelvic Organs
18.21.2.5. By End User
18.22. South Africa
18.22.1. Pricing Analysis
18.22.2. Market Share Analysis, 2022
18.22.2.1. By Product
18.22.2.2. By Procedure
18.22.2.3. By Indication
18.22.2.4. By Pelvic Organs
18.22.2.5. By End User
18.23. Israel
18.23.1. Pricing Analysis
18.23.2. Market Share Analysis, 2022
18.23.2.1. By Product
18.23.2.2. By Procedure
18.23.2.3. By Indication
18.23.2.4. By Pelvic Organs
18.23.2.5. By End User
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Product
19.3.3. By Procedure
19.3.4. By Indication
19.3.5. By Pelvic Organs
19.3.6. By End User
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. Johnson & Johnson Services Inc.
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Coloplast A/S
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Dipromed Srl
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Boston Scientific Corporation
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. pfm medical ag
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Betatech Medical
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. Promedon Group
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Caldera Medical
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. Cook Medical
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. MEGYN PRODUCTS INC.
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
20.1.11. CooperSurgical Inc.
20.1.11.1. Overview
20.1.11.2. Product Portfolio
20.1.11.3. Profitability by Market Segments
20.1.11.4. Sales Footprint
20.1.11.5. Strategy Overview
20.1.11.5.1. Marketing Strategy
20.1.12. DIMA S.L.
20.1.12.1. Overview
20.1.12.2. Product Portfolio
20.1.12.3. Profitability by Market Segments
20.1.12.4. Sales Footprint
20.1.12.5. Strategy Overview
20.1.12.5.1. Marketing Strategy
20.1.13. Digitimer Ltd
20.1.13.1. Overview
20.1.13.2. Product Portfolio
20.1.13.3. Profitability by Market Segments
20.1.13.4. Sales Footprint
20.1.13.5. Strategy Overview
20.1.13.5.1. Marketing Strategy
20.1.14. Bray Group Ltd
20.1.14.1. Overview
20.1.14.2. Product Portfolio
20.1.14.3. Profitability by Market Segments
20.1.14.4. Sales Footprint
20.1.14.5. Strategy Overview
20.1.14.5.1. Marketing Strategy
20.1.15. medesign Ingenieur-Consulting GmbH
20.1.15.1. Overview
20.1.15.2. Product Portfolio
20.1.15.3. Profitability by Market Segments
20.1.15.4. Sales Footprint
20.1.15.5. Strategy Overview
20.1.15.5.1. Marketing Strategy
20.1.16. Panpac Medical Corp.
20.1.16.1. Overview
20.1.16.2. Product Portfolio
20.1.16.3. Profitability by Market Segments
20.1.16.4. Sales Footprint
20.1.16.5. Strategy Overview
20.1.16.5.1. Marketing Strategy
20.1.17. Bioteque America Inc.
20.1.17.1. Overview
20.1.17.2. Product Portfolio
20.1.17.3. Profitability by Market Segments
20.1.17.4. Sales Footprint
20.1.17.5. Strategy Overview
20.1.17.5.1. Marketing Strategy
20.1.18. Mediplus Ltd.
20.1.18.1. Overview
20.1.18.2. Product Portfolio
20.1.18.3. Profitability by Market Segments
20.1.18.4. Sales Footprint
20.1.18.5. Strategy Overview
20.1.18.5.1. Marketing Strategy
20.1.19. nomadic international
20.1.19.1. Overview
20.1.19.2. Product Portfolio
20.1.19.3. Profitability by Market Segments
20.1.19.4. Sales Footprint
20.1.19.5. Strategy Overview
20.1.19.5.1. Marketing Strategy
20.1.20. Dyna Mesh
20.1.20.1. Overview
20.1.20.2. Product Portfolio
20.1.20.3. Profitability by Market Segments
20.1.20.4. Sales Footprint
20.1.20.5. Strategy Overview
20.1.20.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Pelvic Reconstruction Market
